𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster

✍ Scribed by B. Bucher; P. Francioli; B. Geudelin; B. Fritzell; D. Lavanchy; P. C. Frei

Publisher
Springer
Year
1994
Tongue
English
Weight
660 KB
Volume
13
Category
Article
ISSN
0934-9723

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Twelve-year follow-up of a prospective r
Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children
✍ Man-Fung Yuen; Wei-Ling Lim; Chi-Chung Cheng; Shiu-Kam Lam; Ching-Lung Lai πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 49 KB

A total of 318 children were prospectively randomized in group 1 with two 5-g doses of recombinant vaccine given at 0 and 1 month; in group 2 with three 5-g doses of recombinant vaccine given at 0, 1, and 6 months; or in group 3 with three doses of plasma-derived vaccine given at 0, 1, and 6 months.

Characterization of a human monoclonal a
Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine
✍ R.A. Heijtink; J. Kruining; P. van Bergen; S. de Rave; J. van Hattum; M. Schutte πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 204 KB

A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB-VAX: plasmaderived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix-B). 1Ff4 binds preferentially to HBs

Immunogenicity and safety in adults of h
Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later
✍ H. Briem; A. Safary πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 288 KB

## Abstract An inactivated vaccine against hepatitis A was administered as a single 1,440 enzyme‐linked immunosorbent assay (ELISA) units dose at month 0 with a booster at month 6 to 200 subjects divided into two age groups: group 1, 20–39 years (n = 134) and group II, 40–62 years (n = 66). At day

Five-year follow-up of a prospective ran
Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses
✍ Dr. Ching-Lung Lai; Benjamin Chun-Yu Wong; Eng-Kiong Yeoh; Wai-Ling Lim; Wai-Kwa πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 517 KB

In a prospective randomized trial, 318 children aged between 3 mo and 11 yr who were negative for all hepatitis B markers were randomized to receive two 5-pg doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 m o (group 11, three 5 -~g doses of hepatitis B recombinant DNA yeast vaccine at